---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-050327"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T01:58:30.560848+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Incannex adds four OSA experts to IHL-42X advisory board; Phase 2 data July 2025

## Summary
- Appointed Scott Sands, Ali Azarbarzin, Lora McGill, and Nancy Collop to the IHL-42X Clinical Advisory Board.
- Company expects to announce IHL-42X Phase 2 topline data in July 2025.
- Phase 3 US study planned to start later in 2025.
- IHL-42X is an oral once-daily treatment for obstructive sleep apnea (OSA).

## SEC filing metadata
- accession: 0001213900-25-050327
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390025050327/0001213900-25-050327-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390025050327/ea0244374-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-050327
- JSON: https://secwatch.observer/filing/0001213900-25-050327.json
- Plain text: https://secwatch.observer/filing/0001213900-25-050327.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.